EnteroMedics (ETRM) Tops Q2 EPS by 2c, Beats on Revenues

EnteroMedics (NASDAQ: ETRM) reported Q2 EPS of ($0.91), $0.02 better than the analyst estimate of ($0.93). Revenue for the quarter came in at $276 million versus the consensus estimate of $270 million.

Recent Highlights and Accomplishments

• Placed a record 42 vBloc commercial units in the second quarter of 2017, up 83% from a year ago. 34 of these placements were part of the Company\'s recently-launched vBloc Now program
• Launched vBloc Now reduced-cost program with the goal to expedite reimbursement by increasing commercial real-world implants and patient outcomes data for payers
• Announced the acquisition of BarioSurg, Inc. and its minimally invasive Gastric Vest System, and subsequently last week received approval from the MHSSE in Spain to start the Spanish portion of CE Mark study for the Gastric Vest System
• Initiated Kaiser type 2 diabetes trial to study vBloc compared to standard of care treatment for type 2 diabetes
• Entered into a collaboration agreement under which EnteroMedics will modify its vBloc System for use in pre-clinical research by a corporate partner
• Completed first covered vBloc implant for a veteran through the VA Choice Program

For earnings history and earnings-related data on EnteroMedics (ETRM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c